Delivery as the rate-limiting step for cancer vaccines

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Delivery as the rate-limiting step for cancer vaccines

Despite renewed momentum in cancer vaccine development, many programs continue to stall between promising immunogenicity and meaningful clinical benefit. This panel examines how delivery strategy, not immunogenicity alone, is emerging as the critical determinant of clinical and manufacturing success.

Experts will discuss targeting the immune system versus the tumor, platform-specific delivery trade-offs, and how manufacturing and combination regimens constrain what is feasible in practice.

Attend this webinar to:

Understand why delivery, rather than immunogenicity, is increasingly the rate-limiting step separating promising cancer vaccine candidates from clinical success
Compare platform-specific delivery trade-offs and their implications for immune activation against the tumor versus the broader immune system
Learn how manufacturing constraints and combination regimen design shape what delivery strategies are feasible at scale

Dr Prasun Chakraborty

Founder and CEO of Genevation

Dr Prasun Chakraborty is a cancer researcher and biotechnology entrepreneur with more than 18 years of experience in RNA biology, oncology, mRNA technologies, and precision medicine. He is Founder and CEO of Genevation, a biotechnology company developing AI-enabled personalised mRNA cancer vaccines. Genevation integrates AI-driven neoantigen identification with rapid, cell-free mRNA manufacturing to create patient-specific vaccines within approximately 14 days. Dr Chakraborty has held research and scientific roles at GSK, Cytiva, the University of Dundee, and Dana-Farber Cancer Institute/Harvard Medical School. His work focuses on translating RNA biology and cancer immunology into next-generation personalised therapies for patients.

Dr Nora Disis

Helen B. Slonaker Endowed Professor for Cancer Research at University of Washington

Dr Disis is the Helen B. Slonaker Endowed Professor for Cancer Research at the University of Washington (UW), Professor of Medicine and Adjunct Professor of Pathology and Laboratory Medicine and Obstetrics and Gynecology at UW and a Professor at the Fred Hutchinson Cancer Center. She is the Director of UW Medicine’s Cancer Vaccine Institute. Her research interest is in the discovery of new immunologic targets in solid tumors for the development of vaccines for the treatment and prevention of common malignancies. In addition, her group evaluates the use of the immune system to aid in the diagnosis of cancer and develops novel assays and approaches to quantitate and characterize human immunity. She holds several patents in the field of targeted cancer immunotherapy and immune-based diagnostics. Dr Disis is a member of the American Society of Clinical Investigation and the Association of American Physicians. She is an American Cancer Society Professor, a Deputy Editor at JAMA, and the Editor-in-Chief of JAMA Oncology.

Dr Timothy Spear

Physician Scientist in the Division of Oncology at the Children’s Hospital of Philadelphia

Dr Timothy Spear, MD, PhD is a physician scientist in the Division of Oncology at the Children’s Hospital of Philadelphia. He received his MD and PhD at Loyola University studying the cross-reactivity of T cell receptor (TCR) engineered T cells and subsequently completed Pediatrics Residency and Hematology/Oncology Fellowship at CHOP. His research interests are focused on mRNA vaccination strategies for childhood cancers, including personalized neoantigen vaccines and vaccines to enhance the efficacy of cellular therapy.